Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

97 results about "Visceral pain" patented technology

Visceral pain is pain that results from the activation of nociceptors of the thoracic, pelvic, or abdominal viscera (organs). Visceral structures are highly sensitive to distension (stretch), ischemia and inflammation, but relatively insensitive to other stimuli that normally evoke pain such as cutting or burning. Visceral pain is diffuse, difficult to localize and often referred to a distant, usually superficial, structure. It may be accompanied by symptoms such as nausea, vomiting, changes in vital signs as well as emotional manifestations. The pain may be described as sickening, deep, squeezing, and dull. Distinct structural lesions or biochemical abnormalities explain this type of pain in only a proportion of patients. These diseases are grouped under gastrointestinal neuromuscular diseases (GINMD). Others can experience occasional visceral pains, often very intense in nature, without any evidence of structural, biochemical or histolopathologic reason for such symptoms. These diseases are grouped under functional gastrointestinal disorders (FGID) and the pathophysiology and treatment can vary greatly from GINMD. The two major single entities among functional disorders of the gut are functional dyspepsia and irritable bowel syndrome.

Methods for treating visceral pain

The invention features methods of treating visceral pain in humans by administering an effective amount of a 5HT1B or 5HT1D receptor agonist, (e.g., a triptan). These methods can be used, for example, to treat a human suffering from visceral pain secondary to an underlying disease of a visceral organ, such as pancreatitis. Visceral pain treatable by the methods of the invention may also be secondary to a disease of the liver, kidney, ovary, uterus, bladder, bowel, stomach, esophagus, duodenum, intestine, colon, spleen, pancreas, appendix, heart, or peritoneum.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

Therapeutic agent for intestinal diseases and visceral pain

InactiveUS20050148632A1Receptor selectivity is unclearImprove securityBiocideAntipyreticDisease irritable bowelVisceral pain
The present invention relates to a therapeutic agent for irritable bowel syndrome of diarrhea type, ulcerative colitis, visceral pain or abdominal pain, which contains a compound of the following formula and which has 5-HT7 receptor antagonistic effect or an analogue thereof; and this therapeutic agent has an excellent therapeutic effect and a high safety:
Owner:AJINOMOTO CO INC

Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist

InactiveUS20060089371A1Excellent IP receptor antagonistic activitySuitable for productionBiocideOrganic active ingredientsVisceral painHeadaches
The present invention relates to phenyl or heteroaryl amino alkane derivatives of formula (I) in which the groups Q1-Q4, Ar, and R1-R7 are as defined in the specification and claims. These materials are useful as active ingredients of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorders as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since these diseases also are alleviated by treatment with an IP receptor antagonist. The application claims the compounds, pharmaceutical compositions containing them, and methods of treatment using them.
Owner:BAYER HEALTHCARE AG

Method and apparatus for stimulating a bodily hollow system and method and apparatus for measuring reactions to stimuli of such system

The invention relates to a method and an apparatus for stimulating and / or measuring visceral pain in a bodily hollow system of a human being or an animal. The method and apparatus is especially well suited for multi-modal stimulation and measuring, where different stimulus modalities are integrated into one stimulus device. The stimuli may be any one or more of the stimuli: mechanical stimulus, thermal stimulus, chemical stimulus and electric stimulus. The stimuli may activate superficial and deeper layers of the hollow system. Distinct responses to the individual stimuli and robust stimulus-response relations are obtained and result in the possibility of comparative studies of different visceral sensations.
Owner:GREGERSEN HANS

Use of S,S-Reboxetine in the Treatment of Pain

InactiveUS20080261984A1Efficacious in treating painOrganic active ingredientsNervous disorderDiseaseVisceral pain
Use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pain condition selected from neuropathic pain, nociceptive pain, cancer pain, back pain, inflammatory pain, musculo-skeletal disorders, visceral pain, pain from strains / sprains, post-operative pain, posttraumatic pain, burns, renal colic, acute pain, central nervous system trauma, head pain, and orofacial pain, is disclosed. Use of (S,S)-reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of pain in a patient refractory to an alpha-2-delta ligand, and use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use as a mental performance or mood enhancer, are also disclosed.
Owner:PFIZER INC

Fused bicyclic or tricyclic amino acids

The compounds of the instant invention are bicyclic or tricyclic amino acids useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, sleep disorders, visceral pain disorders, and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.
Owner:PFIZER INC

Benzaepinones as sodium channel blockers

Benzazepinone compounds represented by Formula (I), or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, urinary incontinence, pruritis, itchiness, allergic dermatitis, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier.
Owner:MERCK SHARP & DOHME CORP

Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof

Highly selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, visceral pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.
Owner:WYETH

Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine Compounds

InactiveUS20120029006A1Impair pain sensationImproved profileBiocideNervous disorderChronic painVisceral pain
Cis-tetrahydro-spiro(cyclohexane-1,1′-pyrido[3,4-b]indole)-4-amine compounds which act on the nociceptin / ORL-1 receptor system as well as on the μ-opioid receptor system and which are distinguished in particular by selective effectiveness in the treatment of chronic pain, such as inflammatory pain, visceral pain, tumour pain, and neuropathic pain, without at the same time developing pronounced effectiveness against acute, nociceptive pain.
Owner:GRUNENTHAL GMBH

Ambroxol for the treatment of chronic nociceptive pain

A method of treating chronic nociceptive pain, osteoarthritis, irritable bowel syndrome, fibromyalgia, visceral pain, or rheumatoid arthritis in a patient in need thereof, the method comprising administering to the patient ambroxol or a pharmacologically acceptable salt thereof.
Owner:BOEHRINGER INGELHEIM INT GMBH

Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers

The present invention is directed to substituted benzodiazepinones, benzoxazepinones and benzothiazepinones compounds that are sodium channel blockers useful for the treatment of chronic and neuropathic pain. The compounds of the present invention are also useful for the treatment of other conditions, including disorders of the CNS such as anxiety, depression, epilepsy, manic depression and bipolar disorder. This invention also provides pharmaceutical compositions comprising a compound of the present invention, either alone, or in combination with one or more therapeutically active compounds, and a pharmaceutically acceptable carrier. This invention further comprises methods for the treatment of acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain and disorders of the CNS including, but not limited to, epilepsy, manic depression, depression, anxiety and bipolar disorder comprising administering the compounds and pharmaceutical compositions of the present invention.
Owner:MERCK SHARP & DOHME CORP

Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers

Aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds and a pharmaceutically acceptable carrier, and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as initable bowel syndrome, Cnohns disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar depression, and tachy-arrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are described.
Owner:MERCK SHARP & DOHME CORP

Rape bee-pollen extract and use thereof

The invention provides an anti-inflammatory, antalgic and antibacterial extract which is extracted from rape bee-pollen according to lots of process researches. Strict tests prove that the extract has anti-inflammatory, antalgic and antibacterial functions and inhibition effect on human leukocyte elastase, excellent antalgic effect on visceral pain caused by ethylic acid and external pain caused by a hot plate in mice and excellent inhibition effect on Escherichia coli, staphylococcus aureus, pseudomonas aeruginosa, bacillus subtilis and other bacterial. The extract can be used in the development of plant-source anti-inflammatory agents, antalgics and bacteriostatic agents. In addition, China's rape pollen productivity is huge, so the rape pollen can be used as the raw material for the plant-source anti-inflammatory agents, antalgics and bacteriostatic agents; and the extract has the advantages of low cost and simple process flow.
Owner:陕西康泰莱生物医药工程有限公司

Treatments for Gastrointestinal Disorders

The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Owner:IRONWOOD PHARMA

Methods of use for probiotics and prebiotics

The present disclosure relates to method(s) for reducing the risk of visceral pain hypersensitivity, modulating the gut-brain axis, or reducing the local inflammatory response in a subject. The method(s) include providing a nutritional composition that includes Lactobacillus rhamnosus GG (LGG), galacto-oligosaccharide(s) (GOS) and polydextrose (PDX) to the subject. The combination of LGG, GOS, and PDX may exhibit additive or synergistic beneficial health effects when consumed. The nutritional compositions herein are suitable for administration to children and infants.
Owner:MEAD JOHNSON NUTRITION

Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome

The use of 5-HT6 serotonin receptor antagonists of formula (I):or pharmaceutically acceptable salts thereof, is described for the treatment of Irritable Bowel Syndrome and pain in mammals, more particularly inflammatory, neuropathic or visceral pain.
Owner:AXOVANT SCI GMBH

Treatment of visceral pain, E.G., irritable bowel syndrome with nerve-acting agents

Methods are provided for use in treating humans suffering from irritable bowel syndrome. In the subject methods, an effective amount of a nerve-acting agent, e.g., lidocaine, topiramate, mexiletine and gabapentin, etc., is administered to a human suffering from irritable bowel syndrome. Also provided are pharmaceutical compositions and kits for use in practicing the subject methods.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Indole compounds and methods for treating visceral pain

The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D / 1B receptors, by administering to a patient in need thereof a therapeutically effective amount of an indole compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. The methods of the invention may further comprise the administration of additional therapeutic agent. The invention also features new compounds of Formula (I), pharmaceutical compositions thereof, and methods of resolving enantiomeric mixtures.
Owner:NEURAXON INC

Therapeutic proline derivatives

The compounds of formula (I) or a pharmaceutically acceptable salt, solvate or pro-drug thereof, are proline derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, fibromyalgia, arthritis, neuropathalogical disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included. wherein either X is O, S, NH or CH2 and Y is CH2 or a direct bond, or Y is O, S or NH and X is CH2; and R is a 3-12 membered cycloalkyl, 4-12 membered heterocycloalkyl, heteroaryl or aryl, where any ring may be optionally substituted with one or more substituents independently selected from halogen, hydroxy, cyano, nitro, amino, hydroxycarbonyl, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 alkoxy, hydroxyC1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, perfluoro C1-C6 alkyl, perfluoroC1-C6 alkoxy, C1-C6 alkylamino, di-C1-C6 alkylamino, aminoC1-C6 alkyl, C1-C6 alkylaminoC1-C6 alkyl, di-C1-C6 alkylaminoC1-C6 alkyl, C1-C6acyl, C1-C6acyloxy, C1-C6acyloxyC1-C6 alkyl, C1-C6 acylamino, C1-C6 alkylthio, C1-C6 alkylthiocarbonyl, C1-C6 alkylthioxo, C1-C6 alkoxycarbonyl, C1-C6 alkylsulfonyl, C1-C6 alkylsulfonylamino, aminosulfonyl, C1< / highl
Owner:PFIZER INC

Ketorolac tromethamine freezing-dried power injection and preparation method thereof

ActiveCN101167722AOvercoming low bioavailabilityOvercome curative effectOrganic active ingredientsPowder deliveryVisceral painAnalgesics effects
Ketorolac tromethamine is a new type of non-steroidal analgesic and anti-inflammatory drug with strong analgesic effect, which can be administered orally or by injection. It is mainly used to relieve moderate to severe postoperative pain, and Acute renal colic related to trauma, visceral pain related to cancer, anti-inflammatory of local inflammation, etc., the present invention provides a preparation method of ketorolac tromethamine freeze-dried powder preparation, which greatly improves the stability of the main drug, It not only overcomes the shortcoming of slow onset of oral administration, but more importantly, overcomes the problems of unstable main drug of liquid injection and unstable process in actual production.
Owner:LUNAN PHARMA GROUP CORPORATION

Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment

The invention provides methods for treating visceral pain and pain associated with therapy. The compounds useful in the methods of the invention are blockers of sodium ion channels, and in particular compounds that bind to the SS1 or SS2 extracellular mouth of the α-subunit thereof. Particularly useful compounds are saxitoxin and its derivatives and analogues and tetrodotoxin and its derivatives and analogues.
Owner:WEX MEDICAL LTD

Short-chain peptides as Kappa (κ) opioid receptors (KOR) agonist

The present invention relates to novel short-chain peptides of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically accepted salts, or prodrugs thereof which are useful in the treatment or prevention of diseases in which the Kappa (κ) opioid receptors (KOR) are involved, such as treatment or prevention of visceral pain, hyperalgesia, rheumatoid arthritic inflammation, osteoarthritic inflammation, IBD inflammation, IBS inflammation, ocular inflammation, otitic inflammation or autoimmune inflammation. The invention also relates to process for the manufacture of said short-chain peptides, and pharmaceutical compositions containing them and their use.
Owner:CADILA HEALTHCARE LTD

Use of nk-1 receptor antagonists in management of visceral pain

ActiveUS20120028980A1Improving visceral analgesiaBiocideAntipyreticVisceral painWhole body
Methods for managing visceral pain in mammalian subjects are described, in which a NK-1 receptor antagonist is administered to the subject before, during or after administration of general anesthesia. The methods and uses of NK-1 receptor antagonists described herein provide improved visceral pain management and MAC reduction when used with volatile anesthetics for general anesthesia.
Owner:COLORADO STATE UNIVERSITY

Animal model to evaluate visceral pain perception

Animal model to measure visceral pain of a balloon catheter and an implantable sensor module having transcutaneous telemetring ability. The implantable sensor module is set up to receive both visceromotor and pseudoaffective responses of the test animal. In particular, the balloon catheter is an implantable balloon catheter, preferably implanted in the duodenum of the test animal and the implantable sensor is set up to receive input signals form at least one bipolar electrode pair and at least one blood catheter. A method for producing said animal as well as kits comprising a balloon catheter and an implantable sensor module for use in a method for producing said animals are also described.
Owner:JANSSEN PHARMA NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products